Hodgkin Lymphoma in Children Under 5 Years: Do They Behave Differently?

J Pediatr Hematol Oncol. 2022 May 1;44(4):186-190. doi: 10.1097/MPH.0000000000002423. Epub 2022 Mar 16.

Abstract

The median age of presentation for Hodgkin lymphoma (HL) is lower in developing countries with a higher proportion under 5 years of age possibly attributable to the high prevalence of Epstein-Barr virus-driven disease. It is unclear whether the clinical presentation and outcomes of this cohort are different with concern regarding late effects being most pronounced in this age group. We report the outcome of children under 5 years of age enrolled in the InPOG-HL-15-01, the first multicentric collaborative study for newly diagnosed children and adolescents with HL from India. Thirty-five (9%) of the study population was younger than 5 years with a striking male preponderance of 34:1. They were less likely to have bulky disease, mediastinal or splenic involvement. The outcomes appear to be at least as favorable as in the older patient group. Efforts need to be made to evolve treatment strategies that spare this very young cohort from potential late effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Epstein-Barr Virus Infections* / complications
  • Epstein-Barr Virus Infections* / diagnosis
  • Epstein-Barr Virus Infections* / epidemiology
  • Herpesvirus 4, Human
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / therapy
  • Humans
  • Male
  • Mediastinum / pathology
  • Prevalence